Shengtai Pharmaceutical Quick Ratio (SGTI) starting from the third quarter 2013 to third quarter 2012, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Shengtai Pharmaceutical, Inc.  (SGTI)

Shengtai Pharmaceutical's Quick Ratio

SGTI's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2013, Quick Ratio fell to 0.1 below Shengtai Pharmaceutical, Inc. average.

Within Biotechnology & Pharmaceuticals industry 50 other companies have achieved higher Quick Ratio than Shengtai Pharmaceutical in third quarter 2013. While Quick Ratio total ranking in the third quarter 2013 has deteriorated compared to the prior quarter from 2549 to 2606.

Explain Quick Ratio?
How much Cash & cash equivalents SGTI´s has?
What are SGTI´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SGTI Quick Ratio (Mar 31 2013)
Q3		 (Dec 31 2012)
Q2		 (Sep 30 2012)
Q1		 (Jun 30 2012)
Q4		 (Mar 31 2012)
Q3
Y / Y Current Liabilities Change 58.16 % 40.97 % 44.65 % 59.04 % -
Y / Y Cash & cash equivalent Change -35.29 % 204.02 % 30.14 % 38.11 % -
Quick Ratio MRQ 0.1 0.17 0.15 0.16 0.26
SGTI's Total Ranking # 2606 # 2549 # 2654 # 2609 #
Seq. Current Liabilities Change 5.61 % 6.09 % -3.1 % 45.68 % -5.87 %
Seq. Cash & cash equivalent Change -33.34 % 13.93 % -8.28 % -7.11 % 213.2 %



Quick Ratio third quarter 2013 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 51
Healthcare Sector # 366
Overall Market # 2606


Quick Ratio Statistics
High Average Low
0.17 0.13 0.08
(Dec 31 2012)   (Dec 31 2011)




Financial Statements
Shengtai Pharmaceutical's Current Liabilities $ 120 Millions Visit SGTI's Balance sheet
Shengtai Pharmaceutical's Cash & cash equivalent $ 13 Millions Visit SGTI's Balance sheet
Source of SGTI's Sales Visit SGTI's Sales by Geography


Cumulative Shengtai Pharmaceutical's Quick Ratio

SGTI's Quick Ratio for the trailling 12 Months

SGTI Quick Ratio

 (Mar 31 2013)
12 Months		 (Dec 31 2012)
12 Months		 (Sep 30 2012)
12 Months		 (Jun 30 2012)
12 Months		 (Mar 31 2012)
12 Months
Y / Y Current Liabilities TTM Growth 50.41 % 81.64 % 160.63 % 390.73 % -
Y / Y Cash & cash equivalent TTM Growth 28.42 % 127.85 % 133.58 % 331.6 % -
Quick Ratio TTM 0.15 0.18 0.16 0.17 0.17
Total Ranking TTM # 1039 # 1095 # 0 # 0 #
Seq. Current Liabilities TTM Growth 10.84 % 8.83 % 9.69 % 13.68 % 33.85 %
Seq. Cash & cash equivalent TTM Growth -9.41 % 21.01 % 6.8 % 9.69 % 60.73 %

Quick ratio ranking by company, industry and sector >> Back to SGTI Financial Strength Comparisons >> Go to Compare SGTI Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2013 to $119.69 millions, cumulative Quick Ratio decreased to 0.15 below the Shengtai Pharmaceutical, Inc. average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 17 other companies have achieved higher Quick Ratio than Shengtai Pharmaceutical. While Quick Ratio overall ranking has improved so far to 1039, from total ranking during the twelve months ending second quarter 2012 at 1095.

Explain Quick Ratio?
How much Cash & cash equivalents SGTI´s has?
What are SGTI´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 18
Healthcare Sector # 89
Within the Market # 1039


trailing twelve months Quick Ratio Statistics
High Average Low
0.15 0.15 0.14
(Mar 31 2013)   (Dec 31 2012)




Companies with similar Quick Ratio in the quarter ending Mar 31 2013, within Biotechnology & Pharmaceuticals Industry Quick RatioMar 31 2013 MRQ Cash & cash equivalentMar 31 2013 MRQ Current Liabilities
Enzo Biochem Inc  0.27 $ 5.644  Millions$ 20.732  Millions
Xtant Medical Holdings Inc   0.25 $ 2.119  Millions$ 8.441  Millions
Multicell Technologies, Inc.  0.24 $ 0.290  Millions$ 1.201  Millions
Spotlight Innovation Inc.  0.21 $ 0.018  Millions$ 0.087  Millions
Shengtai Pharmaceutical, Inc.  0.10 $ 12.530  Millions$ 119.695  Millions
Oncovista Innovative Therapies, Inc  0.09 $ 0.225  Millions$ 2.371  Millions
Beesfree, Inc.  0.09 $ 0.081  Millions$ 0.877  Millions
Beam Therapeutics Inc   0.08 $ 65.100  Millions$ 778.200  Millions
Rich Pharmaceuticals, Inc.  0.07 $ 0.002  Millions$ 0.024  Millions
Pharmacyte Biotech Inc   0.06 $ 0.199  Millions$ 3.113  Millions
Creative Medical Technology Holdings Inc   0.06 $ 0.001  Millions$ 0.010  Millions
Noho, Inc.  0.05 $ 0.011  Millions$ 0.194  Millions
Ds Healthcare Group, Inc.  0.05 $ 0.197  Millions$ 4.348  Millions
Cullinan Therapeutics Inc   0.04 $ 0.001  Millions$ 0.036  Millions

Date modified: 2026-09-08T15:21:55+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.